日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes

帕博利珠单抗联合紫杉醇治疗 HR+/HER2- 乳腺癌患者,包括 HER2 富集型或基底样亚型

Conte, Benedetta; Brasó-Maristany, Fara; Pascual, Tomás; Hernando, Cristina; Vázquez, Silvia; Blanch, Salvador; Oliveira, Mafalda; Virizuela, Juan Antonio; Muñoz, Montserrat; Seguí, Elia; Rodriguez-Hernandez, Adela; Vidal Losada, Maria Jesus; Galván, Patricia; Castillo, Oleguer; Blasco, Paula; Alva, Manuel; Chic, Nuria; Sanfeliu, Esther; Cano-Crespo, Sara; Salvador, Fernando; Villacampa, Guillermo; Villanueva, Lorea; Ferrero-Cafiero, Juan Manuel; Vivancos, Ana; Prat, Aleix; Ciruelos, Eva

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989]

更正“识别激素受体阳性/HER2阴性乳腺癌新辅助化疗和内分泌治疗引起的治疗反应和分子变化的预测因子:NEOENDO转化研究”:[ESMO Open 9 (2024) 103989]

Schettini, F; Brasó-Maristany, F; Pascual, T; Lorman-Carbó, N; Nucera, S; Bergamino, M; Galván, P; Conte, B; Seguí, E; García Fructuoso, I; Gómez Bravo, R; Rodríguez, A B; Martínez-Sáez, O; Chic, N; Vidal, M; Adamo, B; González-Farre, B; Sanfeliu, E; Cebrecos, I; Mensión, E; Oses, G; Locci, M; Mollà, M; Ganau, S; Jares, P; Vidal-Sicart, S; Muñoz, M; Prat, A

Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer

年轻女性雌激素受体阳性、HER2阴性乳腺癌的基因组和临床特征

Walbaum, B; Martínez-Sáez, O; Brasó-Maristany, F; Seguí, E; Chic, N; Muñoz I Carrillo, J; Antonio Sola, J; Rey, M; Giménez-Xavier, P; Gómez-Bravo, R; García-Fructuoso, I; Pascual, T; Rodriguez-Hernandez, A; Schettini, F; Bergamino, M; González, M; Angelats, L; Adamo, B; Muñoz, M; Sanfeliu, E; Martínez-Pozo, A; Galván, P; Jares, P; Puig-Butillé, J A; Cebrecos, I; Sánchez, C; Prat, A; Vidal, M

Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy

Ki67动态变化可预测接受术前内分泌治疗的雌激素受体阳性/HER2阴性乳腺癌患者的内分泌敏感性

Gómez-Bravo, R; Walbaum, B; Bergamino, M; Martínez-Sáez, O; Schettini, F; Seguí, E; García-Fructuoso, I; Pascual, T; Chic, N; González, M; Rodríguez, A; Rey, M; Giménez-Xavier, P; Blasco, P; Castillo, O; Galván, P; Sanfeliu, E; González-Farré, B; Vidal, M; Adamo, B; Brasó-Maristany, F; Prat, A; Muñoz, M

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study

HER2DX(一种基于算法的基因组诊断方法)对早期HER2阳性乳腺癌临床决策的影响:一项前瞻性真实世界研究的结果

Martínez-Sáez, O; Tapia, M; Marín-Aguilera, M; Hernández-Illán, E; Tébar, C; Martinez-Puchol, A I; Jares, P; Marín-Liébana, S; Magro, A; Puig-Butille, J A; Palomar, L; Sanfeliu, E; Martinez, M T; Losada, M V; Hernando, C; Adamo, B; Iranzo, V; Pascual, T; Pouptsis, A; Schettini, F; Santaballa, A; Conte, B; Torregrosa, M D; Brasó-Maristany, F; Walbaum, B; Gómez-Bravo, R; Burgués, O; Fructuoso, I G; Garrido-Cano, I; Seguí, E; Paré, L; Muñoz, M; Carcelero, E; Sànchez, J; Villagrasa-González, P; Buckingham, W; Prat, A; Villacampa, G; Chic, N; Rivera, P; Rezqallah, A; Saura, C; Escrivà, S; Bermejo, B; Lluch, A; Llombart, A; Cejalvo, J M

A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies

早期三阴性乳腺癌 (TNBC) 中 14 个基因的 B 细胞免疫特征:七项研究的汇总分析

Conte, Benedetta; Brasó-Maristany, Fara; Hernández, Adela Rodríguez; Pascual, Tomás; Villacampa, Guillermo; Schettini, Francesco; Vidal Losada, Maria J; Seguí, Elia; Angelats, Laura; Garcia-Fructuoso, Isabel; Gómez-Bravo, Raquel; Lorman-Carbó, Natàlia; Paré, Laia; Marín-Aguilera, Mercedes; Martínez-Sáez, Olga; Adamo, Barbara; Sanfeliu, Esther; Fratini, Beatrice; Falato, Claudette; Chic, Núria; Vivancos, Ana; Villagrasa, Patricia; Staaf, Johan; Parker, Joel S; Perou, Charles M; Prat, Aleix

Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study

识别激素受体阳性/HER2阴性乳腺癌新辅助化疗和内分泌治疗引起的治疗反应和分子变化的预测因子:NEOENDO转化研究

Schettini, F; Brasó-Maristany, F; Pascual, T; Lorman-Carbó, N; Nucera, S; Bergamino, M; Galván, P; Conte, B; Seguí, E; García Fructuoso, I; Gómez Bravo, R; Rodríguez, A B; Martínez-Sáez, O; Chic, N; Vidal, M; Adamo, B; González-Farre, B; Sanfeliu, E; Cebrecos, I; Mensión, E; Oses, G; Locci, M; Mollà, M; Ganau, S; Jares, P; Vidal-Sicart, S; Muñoz, M; Prat, A

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

利博西尼联合来曲唑或化疗治疗乳腺癌的细胞周期抑制和免疫微环境

Pascual, Tomás; Fernandez-Martinez, Aranzazu; Agrawal, Yash; Pfefferle, Adam D; Chic, Nuria; Brasó-Maristany, Fara; Gonzàlez-Farré, Blanca; Paré, Laia; Villacampa, Guillermo; Saura, Cristina; Hernando, Cristina; Muñoz, Montserrat; Galván, Patricia; Gonzàlez-Farré, Xavier; Oliveira, Mafalda; Gil-Gil, Miguel; Ciruelos, Eva; Villagrasa, Patricia; Gavilá, Joaquín; Prat, Aleix; Perou, Charles M

Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer

早期HER2阳性乳腺癌的转移部位模式与内在亚型和HER2DX的关系

Dieci, Maria Vittoria; Conte, PierFranco; Bisagni, Giancarlo; Bartolini, Stefania; Frassoldati, Antonio; Generali, Daniele; Piacentini, Federico; Griguolo, Gaia; Tagliafico, Enrico; Brasó Maristany, Fara; Chic, Nuria; Paré, Laia; Miglietta, Federica; Vicini, Roberto; D'Amico, Roberto; Balduzzi, Sara; Prat, Aleix; Guarneri, Valentina

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer

哌柏西利和瑞博西利在激素受体阳性乳腺癌中的生物活性比较

Natàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Patricia Galván, Nuria Chic, Isabel Garcia-Fructuoso, Adela Rodríguez, Raquel Gómez-Bravo, Francesco Schettini, Paula Blasco, Oleguer Castillo, Blanca González-Farré, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Charles M Perou,